Fed. Circ. Revives Boehringer Diabetes Drug Patent
The Federal Circuit on Monday reversed a lower court decision invalidating a Boehringer patent on a method of treating Type 2 diabetes that was asserted against Mylan and Aurobindo, ruling that...To view the full article, register now.
Already a subscriber? Click here to view full article